HK1094768A1 - Use of 4-hydroxytamoxifen for the preparation of amedicament for the treatment of gynecomastia - Google Patents

Use of 4-hydroxytamoxifen for the preparation of amedicament for the treatment of gynecomastia

Info

Publication number
HK1094768A1
HK1094768A1 HK07100340A HK07100340A HK1094768A1 HK 1094768 A1 HK1094768 A1 HK 1094768A1 HK 07100340 A HK07100340 A HK 07100340A HK 07100340 A HK07100340 A HK 07100340A HK 1094768 A1 HK1094768 A1 HK 1094768A1
Authority
HK
Hong Kong
Prior art keywords
gynecomastia
hydroxy tamoxifen
patients
patient
amedicament
Prior art date
Application number
HK07100340A
Other languages
English (en)
Inventor
Le Nestour Elisabeth
Andrew R Palumbo
Original Assignee
Besins Int Lab
Ascend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/734,640 external-priority patent/US7786172B2/en
Priority claimed from EP03293156A external-priority patent/EP1550440A1/en
Application filed by Besins Int Lab, Ascend Therapeutics Inc filed Critical Besins Int Lab
Publication of HK1094768A1 publication Critical patent/HK1094768A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0041—Mammary glands, e.g. breasts, udder; Intramammary administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK07100340A 2003-12-15 2007-01-10 Use of 4-hydroxytamoxifen for the preparation of amedicament for the treatment of gynecomastia HK1094768A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/734,640 US7786172B2 (en) 2002-12-18 2003-12-15 Treatment of mastalgia with 4-hydroxy tamoxifen
EP03293156A EP1550440A1 (en) 2003-12-15 2003-12-15 Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
PCT/EP2004/014295 WO2005058297A1 (en) 2003-12-15 2004-12-13 Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia

Publications (1)

Publication Number Publication Date
HK1094768A1 true HK1094768A1 (en) 2007-04-13

Family

ID=34702366

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07100340A HK1094768A1 (en) 2003-12-15 2007-01-10 Use of 4-hydroxytamoxifen for the preparation of amedicament for the treatment of gynecomastia

Country Status (15)

Country Link
EP (1) EP1694319B1 (es)
JP (1) JP5069469B2 (es)
AT (1) ATE401067T1 (es)
AU (1) AU2004298349B2 (es)
CA (1) CA2549824C (es)
DE (1) DE602004015146D1 (es)
DK (1) DK1694319T3 (es)
ES (1) ES2310765T3 (es)
HK (1) HK1094768A1 (es)
MX (1) MXPA06006834A (es)
NO (1) NO336463B1 (es)
NZ (1) NZ547744A (es)
PL (1) PL1694319T3 (es)
PT (1) PT1694319E (es)
WO (1) WO2005058297A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2357726C2 (ru) * 2004-03-22 2009-06-10 Лаборатуар Безен Энтернасьональ Лечение и профилактика доброкачественной опухоли груди 4-гидрокситамоксифеном
US20050208139A1 (en) * 2004-03-22 2005-09-22 Ascend Therapeutics, Inc. Chemically stable compositions of 4-hydroxy tamoxifen
AU2005293712B2 (en) * 2004-10-14 2011-04-21 Besins Healthcare Luxembourg Sarl 4-hydroxy tamoxifen gel formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
EP1210951B1 (en) * 2000-11-30 2005-02-02 Pfizer Products Inc. Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone
CA2448235A1 (en) * 2001-07-31 2003-02-13 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
ATE439829T1 (de) * 2001-12-07 2009-09-15 Besins Int Belgique Gel oder lísung enthaltend dihydrotestosterone, deren herstellungsverfahren und verwendung
NZ544031A (en) * 2003-06-09 2008-08-29 Univ Northwestern Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen

Also Published As

Publication number Publication date
NO336463B1 (no) 2015-08-31
AU2004298349B2 (en) 2010-02-25
EP1694319B1 (en) 2008-07-16
WO2005058297A1 (en) 2005-06-30
PT1694319E (pt) 2008-10-24
DE602004015146D1 (de) 2008-08-28
CA2549824A1 (en) 2005-06-30
JP5069469B2 (ja) 2012-11-07
AU2004298349A1 (en) 2005-06-30
DK1694319T3 (da) 2008-11-17
MXPA06006834A (es) 2006-09-04
CA2549824C (en) 2012-03-13
JP2007529420A (ja) 2007-10-25
EP1694319A1 (en) 2006-08-30
ATE401067T1 (de) 2008-08-15
NZ547744A (en) 2009-09-25
ES2310765T3 (es) 2009-01-16
PL1694319T3 (pl) 2009-01-30
NO20062904L (no) 2006-06-21

Similar Documents

Publication Publication Date Title
NO20054526L (no) Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen
de Vita et al. Breast reconstruction actualized in nipple-sparing mastectomy and direct-to-implant, prepectoral polyurethane positioning: early experience and preliminary results
Schaverien et al. Liposuction for chronic lymphoedema of the upper limb: 5 years of experience
EP2348103A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
CN209695163U (zh) 一种口腔医患气溶胶隔离装置
Kästner et al. Removal of polyacrylamide gel (Aquamid®) from the lip as a solution for late-onset complications: our 8-year experience
HK1094768A1 (en) Use of 4-hydroxytamoxifen for the preparation of amedicament for the treatment of gynecomastia
de la Peña et al. Subfascial gluteal augmentation
EA201270298A1 (ru) Способ лечения злокачественной опухоли
JOP20200046A1 (ar) طرق لعلاج أمراض مرتبطة بـtnf?
Senderoff Practice-based patient management strategies in gluteal augmentation with implants
ATE391499T1 (de) 4-hydroxytamoxifen zur behandlung und prophylaxe von benignen brusterkrankungen
Gonçalves et al. Abdominoplasty with corset plication
CN205649632U (zh) 一种蕲艾温灸贴
ATE252896T1 (de) Endokrintherapie für brustkrebs: kombinierte behandlung mit tamoxifen und alkyl-pcdfs
US20120271216A1 (en) Surgical pin compressive wound dressing housing
CN108245779A (zh) 具有电子理疗功能的贴身穿戴物
CN2621726Y (zh) 中药电热磁疗乳罩
Silicone Gluteal Augmentation in Males A Composite Approach Using Silicone Implant and Lipocell Transfer Douglas S. Steinbrech and Eduardo Gonzalez
Struik Improving Treatment Accuracy and Reducing Side Effects of Breast Conserving Therapy to increase patient satisfaction in early stage breast cancer
PINTO et al. CLINICAL AND HISTOPATHOLOGIC FEATURES OF PLEOMORPHIC ADENOMA: A CASE REPORT
Dholam et al. Implant-retained orbital prosthesis
RU39817U1 (ru) Устройство для рефлексотерапии
KR200413076Y1 (ko) 기능성 건강 발찌
CN201154154Y (zh) 磁疗胸罩